Antiproliferative effect of Baylis-Hillman adducts and a new phthalide derivative on human tumor cell lines

European Journal of Medicinal Chemistry

Volumn 41, Issue 6, 2006, Pages 738-744

  Kohn, Luciana K ^a   Pavam, C H ^a   Veronese, D ^a   Coelho, F ^a   De Carvalho, J E ^a   Almeida, Wanda P ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antiproliferative activity; Baylis Hillman adducts; Cancer; Phthalide

Indexed keywords

2 [(2 CHLORO QUINOLIN 3 YL)HYDROXY METHYL]ACRYLIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; CARBON; METHYL 2 [4 CYANOPHENYL(TERT BUTYLDIMETHYLSILYLOXY)METHYL]ACRYLATE; METHYL 2 [4 TRIFLUOROMETHOXYPHENYL(TERT BUTYLDIMETHYLSILYLOXY)METHYL] ACRYLATE; METHYL 2 [TERT BUTYLDIMETHYLSILYLOXY(4 NITROPHENYL)METHYL]ACRYLATE; METHYL 2 [TERT BUTYLDIMETHYLSILYLOXY(4 TRIFLUOROMETHYLPHENYL)METHYL] ACRYLATE; PHTHALIDE DERIVATIVE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; PHTHALIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYLIS HILLMAN REACTION; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; ELECTRON; FEMALE; HUMAN; HUMAN CELL; MALE; QUALITATIVE RESEARCH; STRUCTURE ACTIVITY RELATION; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMOR CELL LINE;

BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744966570     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.03.006     Document Type: Article

References (16)

1. a, J. Verweij; M.J.A. Jonge, Eur. J. Cancer, 36 (2000), 1479-1487; (b). A. Verdecchia, A. Mariotto, R. Capocaccia, G. Gatta, A. Micheli, M. Sant, F. Berrino, Eur. J. Cancer 37 (2001), 1149-1157; (c). M.D. Garret, P. Workman, Eur. J. Cancer 35 (1999) 2010-2030.
2. Russo A., DeGraff W., Friedman N., and Mitchell J.B. Cancer Res. 46 (1986) 2845-2848
3. Tew K.D. Cancer Res. 54 (1994) 4313-4320
4. Griffith O.W., and Meister A. J. Biol. Chem. 254 (1979) 7558-7560
5. Williamson J.M., Boettcher B., and Meister A. Proc. Natl. Acad. Sci. USA 79 (1982) 6246-6249
6. McCarthy T.J., Hayes E.P., Schwartz C.S., and Witz G. Fundam. Appl. Toxicol. 22 (1994) 543-548
7. a. W.P Almeida, F. Coelho, Tetrahedron Lett., 39 (1998), 8609-8612; b. W.P. Almeida, F. Coelho, Quím. Nova 23 (2000), 98-101; c. M.N. Eberlin, L.S. Santos, W.P. Almeida, C.H. Pavam, F. Coelho, Angew. Chem. Int. Ed. Engl. 43 (2004) 4330-4333.
8. Coelho F., Almeida W.P., Mateus C.R., Veronese D., Lopes E.C.S., Silveira G.P.S., Rossi R.C., and Pavam C.H. Tetrahedron 58 (2002) 7437-7447
9. Mateus C.R., Almeida W.P., Feltrin M.P., Costa A.M., and Coelho F. Tetrahedron 57 (2001) 6901-6908
10. (a) C.H. Pavam, master thesis, Organic Chemistry Department, Chemistry Institute, State Campinas University, SP, Brazil, 2004. (b) F Cœlho, D. Verones, C.H. Pavam, W.I. de Paula, R. Buffon, Tetrahedron 68 (2005), 4563-4572.
11. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757-766
12. 50 of Doxorubicin against NCIADR cell line = 41.2 μM in the same experiments.
13. Donadel O.J., Martin T., Martin V.S., Villar J., and Padron J.M. Bioorg. Med. Chem. Lett. 15 (2005) 3536-3539
14. (a) J. Buck, N.G. Clemo, G. Pattenden. J. Chem. Soc. Perkin Trans 1, (1985), 2399-2405. (b). D.M.T. Chan, T.B. Marder, D. Milstein, N.J. Taylor. J. Am. Chem. Soc., 109 (1987), 6385-6388. (c). G.A. Krafft, J.A. Katzenellenbogen, J. Am. Chem. Soc. 103 (1981) 5459-5466.
15. Litchfield J.T., and Wilcoxon F. J. Pharmacol. Exp. Ther. 96 (1949) 99-149
16. (a) P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd. J. Natl Cancer Inst. 82 (1990), 1107-1118; b. M.R. Boyd and K.D. Paull, Drug Dev. Res. 34 (1995) 91-109.